{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T05:18:59Z","timestamp":1787980739942,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:00:00Z","timestamp":1781913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012352","name":"Universit\u00e0 degli Studi di Milano","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012352","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate whether baseline splenic ^18F-FDG PET uptake and CT-derived spleen volume predict early progression (\u2264\u200936\u00a0months) and progression-free survival (PFS) in diffuse large B cell lymphoma (DLBCL), and whether they interact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>Retrospective cohort of adults with newly diagnosed DLBCL undergoing baseline ^18F-FDG PET\/CT and CT. Splenic PET positivity was defined visually (uptake exceeding hepatic background); spleen volume was measured semi-automatically. Early progression\/relapse was analysed as a 36-month milestone endpoint and PFS as time-to-event. Multivariable logistic and Cox models included IPI, sex, treatment, splenic PET, spleen volume, and a PET\u2009\u00d7\u2009volume interaction. A prespecified PFS sensitivity analysis re-included event-free patients censored before 36\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      124 patients were included (68 men; median age 68\u00a0years [IQR 57\u201377]); 45\/124 (36.3%) were PET-positive; median spleen volume was 3.13\u00a0dL (IQR 1.92\u20135.79). IPI predicted\u2009\u2264\u200936-month progression (OR 1.52;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021) and PFS (HR 1.44;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004). Splenic PET positivity predicted\u2009\u2264\u200936-month progression (OR 2.83;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.048) but not PFS (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.103). The PET\u2009\u00d7\u2009volume interaction was significant (OR 0.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021; HR 0.81;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.033). In PET-negative patients, larger spleen volume predicted higher risk (OR 1.42;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.027; HR 1.22;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.042), whereas volume was neutral in PET-positive cases. In the PFS sensitivity analysis (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u2009145), the interaction attenuated (HR 0.83;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.057) and the PET-negative volume effect was borderline (HR 1.21;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.053).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Splenic PET positivity is a dominant risk marker in DLBCL in this cohort. CT-derived spleen volume may add conditional prognostic information in PET-negative patients, but the incremental value of the PET\u2009\u00d7\u2009volume interaction is modest and requires external validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11547-026-02233-w","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T09:16:16Z","timestamp":1781946976000},"page":"1292-1304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Splenic FDG PET uptake and CT volume as prognostic biomarkers in diffuse large B cell lymphoma"],"prefix":"10.1007","volume":"131","author":[{"given":"Jacopo","family":"D\u2019Argenzio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Rampi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6564-6724","authenticated-orcid":false,"given":"Jacopo","family":"Pozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Vespro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Pavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Casiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca G.","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Castello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura. V.","family":"Forzenigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Castellani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Zilocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Passamonti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpaolo","family":"Carrafiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,20]]},"reference":[{"key":"2233_CR1","doi-asserted-by":"publisher","unstructured":"JO A, RD G, MA L, F C (2017) Non-Hodgkin lymphoma. The Lancet 390:298\u2013310. https:\/\/doi.org\/10.1016\/S0140-6736(16)32407-2","DOI":"10.1016\/S0140-6736(16)32407-2"},{"key":"2233_CR2","doi-asserted-by":"publisher","unstructured":"B C (2002) Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin\u2019s lymphoma. Seminars in Oncology 29:18\u201322. https:\/\/doi.org\/10.1053\/sonc.2002.32749","DOI":"10.1053\/sonc.2002.32749"},{"issue":"5","key":"2233_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/ajh.26151","volume":"96","author":"S Susanibar-Adaniya","year":"2021","unstructured":"Susanibar-Adaniya S, Barta SK (2021) 2021 update on diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management. American J Hematol 96(5):617\u2013629","journal-title":"American J Hematol"},{"key":"2233_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"Project IN-HLPF","year":"1993","unstructured":"Project IN-HLPF (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994. https:\/\/doi.org\/10.1056\/NEJM199309303291402","journal-title":"N Engl J Med"},{"key":"2233_CR5","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"C Bd","year":"2014","unstructured":"Bd C, Ri F, Sf B et al (2014) Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the lugano classification. JCO 32:3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"JCO"},{"key":"2233_CR6","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2967\/jnumed.123.266322","volume":"65","author":"KB Girum","year":"2024","unstructured":"Girum KB, Cottereau A-S, Vercellino L et al (2024) Tumor location relative to the spleen Is a prognostic factor in lymphoma patients: a demonstration from the REMARC trial. J Nucl Med 65:313\u2013319. https:\/\/doi.org\/10.2967\/jnumed.123.266322","journal-title":"J Nucl Med"},{"key":"2233_CR7","doi-asserted-by":"publisher","unstructured":"S W, H J, Y B, others (2023) The prognostic value of splenic abnormalities in pretreatment 18F-FDG PET\/CT in patients with complete response diffuse large B-cell lymphoma. Clinical Radiology 78:375\u2013380. https:\/\/doi.org\/10.1016\/j.crad.2023.02.001","DOI":"10.1016\/j.crad.2023.02.001"},{"issue":"9","key":"2233_CR8","doi-asserted-by":"publisher","first-page":"6374","DOI":"10.21037\/qims-24-180","volume":"14","author":"Z Zhao","year":"2024","unstructured":"Zhao Z, Zhou Y, Yao X, Ge S, Sang S, Yang Y, Zhang B, Deng S (2024) Prognostic significance of diffuse increased fluorine-18-fluorodeoxyglucose (18F-FDG) uptake within the reticuloendothelial system in lymphoma patients. Quant Imaging Med Surg 14(9):6374\u20136385","journal-title":"Quant Imaging Med Surg"},{"issue":"11","key":"2233_CR9","first-page":"3631","volume":"109","author":"K Izumiyama","year":"2024","unstructured":"Izumiyama K, Inao T, Goto H, Harada S, Senjo H, Suto K, Hashiguchi J, Ogasawara R, Saga T, Igarashi T, Wakasa K (2024) Event-free survival at 36 months is a suitable endpoint for diffuse large B-cell lymphoma patients treated with immunochemotherapy: real-world evidence from the North Japan Hematology Study Group. Haematologica 109(11):3631","journal-title":"Haematologica"},{"key":"2233_CR10","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/bjh.16300","volume":"189","author":"C Thieblemont","year":"2020","unstructured":"Thieblemont C, Howlett S, Casasnovas R et al (2020) Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. Br J Haematol 189:84\u201396. https:\/\/doi.org\/10.1111\/bjh.16300","journal-title":"Br J Haematol"},{"key":"2233_CR11","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-020-00900-7","volume":"13","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Martelli M, Trn\u011bn\u00fd M et al (2020) A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. J Hematol Oncol 13:71. https:\/\/doi.org\/10.1186\/s13045-020-00900-7","journal-title":"J Hematol Oncol"},{"key":"2233_CR12","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH et al (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386:351\u2013363. https:\/\/doi.org\/10.1056\/NEJMoa2115304","journal-title":"N Engl J Med"},{"issue":"151","key":"2233_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jclinepi.2022.08.016","volume":"1","author":"MW Heymans","year":"2022","unstructured":"Heymans MW, Twisk JW (2022) Handling missing data in clinical research. J Clin Epidemiol 1(151):185\u2013188","journal-title":"J Clin Epidemiol"},{"key":"2233_CR14","doi-asserted-by":"publisher","unstructured":"R A, C A, I A, others (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748. https:\/\/doi.org\/10.1038\/s41375-022-01620-2","DOI":"10.1038\/s41375-022-01620-2"},{"key":"2233_CR15","first-page":"1072","volume":"44","author":"JN Rini","year":"2003","unstructured":"Rini JN, Leonidas JC, Tomas MB, Palestro CJ (2003) 18F-FDG PET Versus CT for evaluating the spleen during initial staging of lymphoma. J Nucl Med 44:1072\u20131074","journal-title":"J Nucl Med"},{"key":"2233_CR16","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","volume":"32","author":"SF Barrington","year":"2014","unstructured":"Barrington SF, Mikhaeel NG, Kostakoglu L et al (2014) Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048\u20133058. https:\/\/doi.org\/10.1200\/JCO.2013.53.5229","journal-title":"J Clin Oncol"},{"key":"2233_CR17","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP (1996) Forming inferences about some intraclass correlation coefficients. Psychol Methods 1:30\u201346. https:\/\/doi.org\/10.1037\/1082-989X.1.1.30","journal-title":"Psychol Methods"},{"key":"2233_CR18","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86:420\u2013428. https:\/\/doi.org\/10.1037\/0033-2909.86.2.420","journal-title":"Psychol Bull"},{"key":"2233_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","volume":"15","author":"TK Koo","year":"2016","unstructured":"Koo TK, Li MY (2016) A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med 15:155\u2013163. https:\/\/doi.org\/10.1016\/j.jcm.2016.02.012","journal-title":"J Chiropr Med"},{"key":"2233_CR20","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","volume":"1","author":"JM Bland","year":"1986","unstructured":"Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1:307\u2013310","journal-title":"Lancet"},{"key":"2233_CR21","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jclinepi.2010.03.002","volume":"64","author":"J Kottner","year":"2011","unstructured":"Kottner J, Audig\u00e9 L, Brorson S et al (2011) Guidelines for reporting reliability and agreement studies (GRRAS) were proposed. J Clin Epidemiol 64:96\u2013106. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.03.002","journal-title":"J Clin Epidemiol"},{"key":"2233_CR22","doi-asserted-by":"crossref","unstructured":"Hothorn T (2001) maxstat: Maximally Selected Rank Statistics. 0.7\u201326","DOI":"10.32614\/CRAN.package.maxstat"},{"issue":"4","key":"2233_CR23","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2967\/jnumed.122.264740","volume":"64","author":"L Michaud","year":"2023","unstructured":"Michaud L, Bantilan K, Mauguen A, Moskowitz CH, Zelenetz AD, Sch\u00f6der H (2023) Prognostic value of 18F-FDG PET\/CT in diffuse large B-cell lymphoma treated with a risk-adapted immunochemotherapy regimen. J Nucl Med 64(4):536\u2013541","journal-title":"J Nucl Med"},{"issue":"1","key":"2233_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/ajh.26744","volume":"98","author":"C Radkiewicz","year":"2023","unstructured":"Radkiewicz C, Bruchfeld JB, Weibull CE, Jeppesen ML, Frederiksen H, Lambe M, Jakobsen L, El-Galaly TC, Smedby KE, W\u00e4sterlid T (2023) Sex differences in lymphoma incidence and mortality by subtype: a population-based study. American J Hematol 98(1):23\u201330","journal-title":"American J Hematol"},{"issue":"9","key":"2233_CR25","doi-asserted-by":"publisher","first-page":"e37290","DOI":"10.1097\/MD.0000000000037290","volume":"103","author":"R Kozuki","year":"2024","unstructured":"Kozuki R, Sugimoto T, Goto H, Miyamoto N, Hirakawa Y, Umeno A, Idei M, Tagawa S, Namba F, Tani R, Ohmori M (2024) Optimal index for detecting splenic involvement on 18F-fluorodeoxyglucose positron emission tomography\/computed tomography imaging in diffuse large B-cell lymphoma. Medicine 103(9):e37290","journal-title":"Medicine"},{"key":"2233_CR26","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3324\/haematol.2021.278663","volume":"107","author":"L Kostakoglu","year":"2022","unstructured":"Kostakoglu L, Mattiello F, Martelli M et al (2022) Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. Haematologica 107:1633\u20131642. https:\/\/doi.org\/10.3324\/haematol.2021.278663","journal-title":"Haematologica"},{"key":"2233_CR27","doi-asserted-by":"publisher","first-page":"e0210224","DOI":"10.1371\/journal.pone.0210224","volume":"14","author":"B Guo","year":"2019","unstructured":"Guo B, Tan X, Ke Q, Cen H (2019) Prognostic value of baseline metabolic tumor volume and total lesion glycolysis in patients with lymphoma: a meta-analysis. PLoS ONE 14:e0210224. https:\/\/doi.org\/10.1371\/journal.pone.0210224","journal-title":"PLoS ONE"},{"key":"2233_CR28","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1200\/JCO.21.02063","volume":"40","author":"NG Mikhaeel","year":"2022","unstructured":"Mikhaeel NG, Heymans MW, Eertink JJ et al (2022) Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: international metabolic prognostic index. J Clin Oncol 40:2352\u20132360. https:\/\/doi.org\/10.1200\/JCO.21.02063","journal-title":"J Clin Oncol"},{"key":"2233_CR29","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1182\/blood.2022018558","volume":"141","author":"JJ Eertink","year":"2023","unstructured":"Eertink JJ, Zwezerijnen GJC, Heymans MW et al (2023) Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma. Blood 141:3055\u20133064. https:\/\/doi.org\/10.1182\/blood.2022018558","journal-title":"Blood"},{"key":"2233_CR30","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2147\/CMAR.S522628","volume":"31","author":"Y Li","year":"2025","unstructured":"Li Y, Wu D, Tian M (2025) Correlation of PET\/CT maximal standardized uptake values with clinicopathologic parameters of aggressive non-Hodgkin\u2019s lymphoma. Cancer Manag Res 31:975\u2013984","journal-title":"Cancer Manag Res"},{"issue":"11","key":"2233_CR31","doi-asserted-by":"publisher","first-page":"1515097","DOI":"10.3389\/fmed.2024.1515097","volume":"29","author":"P Efstratiou","year":"2025","unstructured":"Efstratiou P, Damianaki A, Kavidopoulou A, Ioannidou P, Markaki E, Skianis IM, Tsagliotis E, Kaliafentaki V, Mattheakakis A, Ximeri M, Manouras E (2025) Myeloid-derived suppressor cells exhibit distinct characteristics in bone marrow and blood of individuals with diffuse large B-cell lymphoma. Front Med 29(11):1515097","journal-title":"Front Med"},{"issue":"11","key":"2233_CR32","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.3389\/fimmu.2020.01126","volume":"5","author":"C Wu","year":"2020","unstructured":"Wu C, Hua Q, Zheng L (2020) Generation of myeloid cells in cancer: the spleen matters. Front Immunol 5(11):1126","journal-title":"Front Immunol"},{"key":"2233_CR33","first-page":"15173","volume":"8","author":"C Wu","year":"2015","unstructured":"Wu C, Wu X, Zhang X et al (2015) Prognostic significance of peripheral monocytic myeloid-derived suppressor cells and monocytes in patients newly diagnosed with diffuse large b-cell lymphoma. Int J Clin Exp Med 8:15173\u201315181","journal-title":"Int J Clin Exp Med"},{"key":"2233_CR34","doi-asserted-by":"publisher","unstructured":"MG L, JK S, EC J, RM S (2013) Assessing splenomegaly. Academic Radiology 20:675\u2013684. https:\/\/doi.org\/10.1016\/j.acra.2013.02.014","DOI":"10.1016\/j.acra.2013.02.014"},{"issue":"3","key":"2233_CR35","doi-asserted-by":"publisher","first-page":"e0213551","DOI":"10.1371\/journal.pone.0213551","volume":"14","author":"D Berzaczy","year":"2019","unstructured":"Berzaczy D, Haug AR, Raderer M, Kiesewetter B, Berzaczy G, Weber M, Mayerhoefer ME (2019) Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F] FDG-PET controlled study. PLoS ONE 14(3):e0213551","journal-title":"PLoS ONE"},{"key":"2233_CR36","doi-asserted-by":"publisher","unstructured":"GS C, JB R, DG A, KGM M (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 162:55\u201363. https:\/\/doi.org\/10.7326\/M14-0697","DOI":"10.7326\/M14-0697"},{"key":"2233_CR37","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJG et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42:328\u2013354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2233_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00259-017-3740-2","volume":"44","author":"N Aide","year":"2017","unstructured":"Aide N, Lasnon C, Veit-Haibach P et al (2017) EANM\/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging 44:17\u201331. https:\/\/doi.org\/10.1007\/s00259-017-3740-2","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"24","key":"2233_CR39","doi-asserted-by":"publisher","first-page":"3632","DOI":"10.3390\/diagnostics13243632","volume":"13","author":"JA Cheng","year":"2023","unstructured":"Cheng JA, Lin YC, Lin Y, Wu RC, Lu HY, Yang LY, Chiang HJ, Juan YH, Lai YC, Lin G (2023) Machine learning radiomics signature for differentiating lymphoma versus benign splenomegaly on CT. Diagnostics 13(24):3632","journal-title":"Diagnostics"},{"key":"2233_CR40","doi-asserted-by":"publisher","unstructured":"J S, H W, M X, others (2024) The value of radiomics features of the spleen as surrogates for differentiating subtypes of common pediatric lymphomas. Quantitative Imaging in Medicine and Surgery 14:5630\u20135641. https:\/\/doi.org\/10.21037\/qims-24-100","DOI":"10.21037\/qims-24-100"},{"key":"2233_CR41","doi-asserted-by":"publisher","unstructured":"CP R, C K, J F, et al (2018) Discriminatory CT-textural features in splenic infiltration of lymphoma versus splenomegaly in liver cirrhosis versus normal spleens in controls and evaluation of their role for longitudinal lymphoma monitoring. European Journal of Radiology 104:129\u2013135. https:\/\/doi.org\/10.1016\/j.ejrad.2018.05.019","DOI":"10.1016\/j.ejrad.2018.05.019"},{"key":"2233_CR42","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2147\/CMAR.S511796","volume":"17","author":"LX Wu","year":"2025","unstructured":"Wu LX, Ding N, Ji YD, Zhang YC, Li MJ, Shen JC, Hu HT, Jin L, Yin SN (2025) Habitat analysis in tumor imaging: advancing precision medicine through radiomic subregion segmentation. Cancer Manag Res 17:731\u2013741. https:\/\/doi.org\/10.2147\/CMAR.S511796","journal-title":"Cancer Manag Res"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-026-02233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-026-02233-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-026-02233-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:50:49Z","timestamp":1787979049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-026-02233-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,20]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["2233"],"URL":"https:\/\/doi.org\/10.1007\/s11547-026-02233-w","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,20]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Committee Lombardia 3 (Protocol ID: 6002_21.05.2025_P).","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided informed consent before scanning. Due to the retrospective design of the study, the requirement for informed consent for the use of patients\u2019 data for research purposes was waived by the Ethics Committee.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}